September 2022: Switzerland Update

An update posted on the Swissmedic website on September 05, 2022,  provides further details regarding an online information event, to cover the new and changed requirements and clarify the specifications in Switzerland, for in vitro diagnostic devices (IVDs). The event is scheduled to be held on November 3, 2022. Participation is free of charge and the presentation will be given in German with simultaneous interpretation into French. During the event, the slides will be shown in German and French.

Following the event, the slide sets will be published on the Swissmedic website in English, French, German and Italian.

The registration form for participating in the event is now available on the Swissmedic website. The deadline for registration is October 14, 2022.

The schedule and the list of speakers have also been published on the website.

More information can be found here.

May 2022: Switzerland Update

An update posted on the Kofam portal on May 27, 2022, informs users of the most important new developments and changes relating to clinical trials with in-vitro diagnostic products (IVDs) which  are regulated by the Ordinance on Clinical Trials with Medical Devices (ClinO-MD) from May 26, 2022.

According to the update, in addition to the existing obligation to prospectively register clinical trials with IVDs, the results of trials with IVDs must now also be published in a trial registry. This also applies to clinical trials with IVDs already underway when the ClinO-MD entered into force on 26 May 2022. The updated ClinO-MD is also now available.

The update further informs users of the categorization of IVDs and classification of clinical trials regulated under ClinO-MD into clinical investigation and performance studies.

An online information event, to cover the new and changed requirements and clarify the specifications in Switzerland will be held on  3 November 2022. Participation is free of charge and individual presentations will be provided on the Swissmedic website in German, French, Italian, and English a few days before the event.  The presentations during the event will be given in German and will be interpreted simultaneously into French. The event will not be recorded. The presentations can not be viewed at a later date.

More information can be found here.

May 2022: Switzerland Update

An update posted on the SwissMedic portal on May 26, 2022, informs users of the change in legal requirements for clinical trials with in-vitro diagnostic products (IVDs) in Switzerland.

From 26 May 2022, at the same time as the application of the In Vitro Diagnostics Regulation (IVDR) in the EU, clinical trials with in vitro diagnostic medical devices will be regulated in the Ordinance on Clinical Trials with Medical Devices (CTO-MedD) and no longer in the Ordinance on Clinical Trials (ClinO).

These new transitional periods in the EU have also been taken into account accordingly in the Swiss Ordinance on In Vitro Diagnostic Medical Devices (IvDO). To avoid jeopardizing a sufficient supply of medical devices to Switzerland, the Federal Council has set lengthy transitional periods – over one year for most devices – for designating the CH-REP.

More information can be found here.

Switzerland Update

An update posted on the Kofam portal on March 10, 2022, informs users of the change in legal requirements for clinical trials with in-vitro diagnostic products (IVDs) in Switzerland.

Clinical trials using IVDs, a special sub-group of medical devices, were regulated in the Clinical Trials Ordinance, (ClinO).  In the process of adapting the Swiss legislation to the new EU Medical Device Regulation (MDR) and the new EU regulation on IVDs (EU-IVDR), clinical research with IVDs in Switzerland will now also be regulated in the Ordinance on clinical trials with medical devices (ClinO-MD).

The changes would be effective from 26 May 2022, the same time as EU-IVDR.  From this date, the Clinical Trials Ordinance (ClinO) will only contain provisions for clinical trials with medicinal products, transplant products and transplantation, and other clinical trials.

Until the amended ClinO-MD comes into force, further information for applicants will be updated on the Kofam website, in a timely manner.

More information can be found here.

Hungary Update

OGEYI, Hungary, posted an update regarding the procedure for authorization of new clinical trials under Regulation 536/2014 on February 24, 2022.

According to the update, the application must be submitted through the CTIS system and all communication will take place on the CTIS interface. Sponsors can either submit Part I and Part II documents together or can choose to submit Part II within two years of authorisation.

The Member States will carry out formal checks, and if the designated Member State does not assume the role of reporting Member State (RMS), then an RMS would be selected. The RMS would then notify the principal and the other member states that it is acting as a reporting Member State. On the 10th day, the RMS will notify the principal of any deficiencies in the documentation. Sponsors should provide the missing documents within 10 days. Member states will assess the new documents within 5 days and the RMS would then notify the principal about the fate of the application, latest by the 25th day.

In cases where Part II documentation is submitted later, OGEYI will carry out the formal check and notify the client of any deficiencies in documentation within 10 days. If required, the applicant must submit the missing documents within 10 days. The OGYÉI will notify the client of the fate of the application within 5 days of receiving the missing documents.

Evaluation

The RMS will forward Part I of the evaluation report (RFI Part I) to the principal and the other Member States concerned within 45 days of validation, along with its conclusions. If required, the client must answer the questions and also submit the requested documentation. (Response to RFI).

For part II documents, the ethics committee (ETT-KFEB) will prepare Part II of the evaluation report within 45 days of validation and the OGYÉI will notify the client of the comments. (Part II RFI). In the case of complete documentation, the OGYÉI shall make the Part II RFI available at the same time as Part I of the evaluation report. If required, the client must answer the questions within 12 days and also submit the requested documentation.

If a reply is not received by the deadline for both Part I and II requests, the CTIS will be closed and the authorisation procedure will be terminated.

Member States have 19 days to assess the information received. On the 76th day, the reporting Member State will finalise the Part I and/or Part II evaluation report taking into account the additional information and will notify the principal of the outcome of the evaluation. (Final Conclusion).

 

February 2022: Hungary Update

OGEYI, Hungary, specified the requirements in English for the documents to be submitted with Part I and II  application for clinical trial authorization on February 23, 2022.

Requirements to be entered into Clinical Trial Information System (CTIS) in Part I and II are elaborated for following sections:

  • Annex I
  • Cover Letter
  • Protocol
  • Labelling of Investigational Medicinal Product
  • Subject Information and Informed Consent
  • Suitability of Investigator
  • Suitability of Facilities

Additionally, templates for investigator CV and site suitability have also been uploaded on the website.

More information can be found here.

February 2022: Hungary Update

National Institute of Pharmacy and Food Health (OGYEI), Hungary announced that the electronic administration at OGEYI will be suspended from 17:00 on  February 10, 2022, to 09:00 on  February 14, 2022, due to the relocation of IT systems. During this period, although submissions can be made to the Office Gate of the OGYÉI and to the CESP interface, their receipts and processing will be carried out only after the restart of internal systems.

As the planned outage would result in a 4-hour-a-day interruption in electronic administration, the duration of the outage,  would not be counted against the deadline for administration.

More information can be found here.